Pilar Ma Samper Ots1, Julia Luisa Muñoz García2, Yesika Ríos Kavadoy2, Ma Luz Couselo Paniagua3, Elena Villafranca Iturre4, Milagrosa Rodríguez Liñán5, Ana María Pérez Casas6, Rodrigo Muelas Soria7, Blanca Ludeña Martínez8, José López Torrecilla9, Manuel Casaña Giner10, Almudena Zapatero Laborda11, Ma Magdalena Márquez García-Salazar12. 1. Department of Radiation Oncology, Rey Juan Carlos Hospital, Madrid, Spain. 2. Department of Radiation Oncology, Infanta Cristina Hospital, Madrid, Spain. 3. Department of Radiation Oncology, Gómez Ulla Hospital, Spain. 4. Department of Radiation Oncology, Navarra Hospital, Spain. 5. Department of Radiation Oncology, Reina Sofía Hospital, Spain. 6. Department of Radiation Oncology, Jiménez Díaz Hospital, Spain. 7. Department of Radiation Oncology, Provincial Hospital of Castellón, Spain. 8. Department of Radiation Oncology, Fuenlabrada Hospital, Spain. 9. Department of Radiation Oncology, General University Hospital of Valencia, Spain. 10. Department of Radiation Oncology, Fundación IVO Valencia, Spain. 11. Department of Radiation Oncology, La Princesa Hospital, Spain. 12. Department of Radiation Oncology, Juan Ramón Jiménez Hospital, Spain.
Abstract
AIM: To assess the prevalence of metabolic syndrome (MetS) and osteoporosis in patients with prostate cancer (PCa) treated with radical radiotherapy (RT) with or without androgen deprivation therapy (ADT). BACKGROUND: Worldwide, the prevalence of MetS is estimated to range from 20% to 25% of the adult population. However, prevalence rates are much higher in PCa patients (pts) who undergo ADT. MATERIALS AND METHODS: Multicentre cross-sectional study of 270 pts in Spain with PCa. Patients were divided into 3 groups based on the duration of ADT (6, 12-18, ≥24 months) and compared to a control group without ADT. MetS was defined according to NCEP ATP III criteria. Osteoporosis was assessed by DEXA. RESULTS: A total of 270 pts, treated from November 2011 to October 2012, were included. Of these, 122 pts (47%) fulfilled the criteria for MetS. The median age of this group was significantly higher (71.3 vs. 69.38 years, p = 0.028). MetS prevalence was 50% in the control group. In pts who received ADT, prevalence was 44.8% after 6 months of ADT, 45.3% after 12-18 months, and 50% after ≥24 months (pns). Most pts (168/270; 62%) underwent DEXA. Of those tested, 78 (46.4%) had osteopenia and only 11 (6.5%) had osteoporosis. CONCLUSIONS: The prevalence of MetS in pts with PCa treated with radical RT was higher (47%) than in the general population. However, there were no significant differences in the duration of ADT administration. The prevalence of osteoporosis was low. These findings suggest that the prevalence of MetS in PCa patients may be higher than previously reported.
AIM: To assess the prevalence of metabolic syndrome (MetS) and osteoporosis in patients with prostate cancer (PCa) treated with radical radiotherapy (RT) with or without androgen deprivation therapy (ADT). BACKGROUND: Worldwide, the prevalence of MetS is estimated to range from 20% to 25% of the adult population. However, prevalence rates are much higher in PCa patients (pts) who undergo ADT. MATERIALS AND METHODS: Multicentre cross-sectional study of 270 pts in Spain with PCa. Patients were divided into 3 groups based on the duration of ADT (6, 12-18, ≥24 months) and compared to a control group without ADT. MetS was defined according to NCEP ATP III criteria. Osteoporosis was assessed by DEXA. RESULTS: A total of 270 pts, treated from November 2011 to October 2012, were included. Of these, 122 pts (47%) fulfilled the criteria for MetS. The median age of this group was significantly higher (71.3 vs. 69.38 years, p = 0.028). MetS prevalence was 50% in the control group. In pts who received ADT, prevalence was 44.8% after 6 months of ADT, 45.3% after 12-18 months, and 50% after ≥24 months (pns). Most pts (168/270; 62%) underwent DEXA. Of those tested, 78 (46.4%) had osteopenia and only 11 (6.5%) had osteoporosis. CONCLUSIONS: The prevalence of MetS in pts with PCa treated with radical RT was higher (47%) than in the general population. However, there were no significant differences in the duration of ADT administration. The prevalence of osteoporosis was low. These findings suggest that the prevalence of MetS in PCa patients may be higher than previously reported.
Entities:
Keywords:
Androgen deprivation therapy; Metabolic syndrome; Osteoporosis; Prostate cancer
Authors: Juan Morote; Antonio Gómez-Caamaño; José L Alvarez-Ossorio; Daniel Pesqueira; Angel Tabernero; Francisco Gómez Veiga; José A Lorente; Mariano Porras; Juan J Lobato; María J Ribal; Jacques Planas Journal: J Urol Date: 2014-12-23 Impact factor: 7.450
Authors: Terrence H Diamond; Joseph Bucci; John H Kersley; Peter Aslan; William B Lynch; Carl Bryant Journal: J Urol Date: 2004-08 Impact factor: 7.450
Authors: Enrique Diaz-Convalia; Miguel Angel Arrabal-Polo; Maria Del Carmen Cano-Garcia; Alejandro Dominguez-Amillo; Nelson Canales-Casco; Miguel Arrabal-Martin Journal: Int Urol Nephrol Date: 2018-01-27 Impact factor: 2.370